CONTACT INFORMATION (SAMPLE LETTER Follows)
Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court, Suite 200 • South San Francisco, CA 94080 • ph: +1 650-624-6900; fax: +1 650-589-1501

ACTELION PHARMACEUTICALS MANAGEMENT
CEO: Jean-Paul.Clozel@actelion.com
Senior Vice President: martine.clozel@actelion.com
Senior Vice President: walter.fischli@actelion.com
Head of Drug Discovery Chemistry: Thomas.Weller@actelion.com
PR and Congress Manager: Karen.Scott@actelion.com
Regulatory Affairs Manager: Emi.Nagata@actelion.com
Actelion Territory Manager: Chris.Amabile@actelion.com
Medical Account Manager: Max.Niederer@actelion.com
Key Account Manager: Lee.Campbell@actelion.com
UK General Manager: Frances.MacDonald@actelion.com; ph: 020 8987 3320; fax: 020 8987 3322; cell: 0778626

ALL EMAILS PERTAINING TO THIS ALERT
Jean-Paul.Clozel@actelion.com, martine.clozel@actelion.com, walter.fischli@actelion.com, Thomas.Weller@actelion.com, Karen.Scott@actelion.com, Emi.Nagata@actelion.com, hris.Amabile@actelion.com, Max.Niederer@actelion.com, Lee.Campbell@actelion.com, Frances.MacDonald@actelion.com, benelux@actelion.com, info.brasil@actelion.com, jobs.ch@actelion.com, Jobs.Jp@actelion.com, jobs.US@actelion.com, Henric.Juserius@actelion.com, Peter.Bergentoft@actelion.com, alexander.treiber@actelion.com, andrea.lauer@actelion.com, andrew.oakley@actelion.com, annick.schwebig@actelion.com, asa.magnusson@actelion.com, carmela.gnerre@actelion.com, catharina.eriksson@actelion.com, christian.rufener@actelion.com, Christoph.binkert@actelion.com, christoph.boss@actelion.com, daniel.bur@actelion.com, dee.loubriel@actelion.com, francois.jenck@actelion.com, han.brouwer@actelion.com, heidemarie.kletzl@actelion.com, heinz.fretz@actelion.com, helga.wiegand@actelion.com, Joel.Freyss@Actelion.Com, josef.goetz@altanapharma.com, julien.pothier@actelion.com, jutta.wiemhoff@actelion.com, karen.lammertyn@actelion.com, lars.prade@actelion.com, lionel.cottin@actelion.com, liz.cook@actelion.com, mary-beth.turner@actelion.com, michael.danzl@actelion.com, michael.halstead@actelion.com, modest.korff@actelion.com, olivier.morand@actelion.com, oliver.nayler@actelion.com, paul.cox@actelion.com, Peggy.Heger@ACTELION.COM, peter.herrmann@actelion.com, ralf.koberstein@actelion.com, roland.haefeli@actelion.com, Rolf.Studer@Actelion.Com, stephan.buchmann@actelion.com, stephanie.combes@actelion.com, volker.breu@actelion.com, per.nilsson@actelion.com, Sarah.Ruppert@actelion.com, denise.hilpert@actelion.com, martin.bolli@actelion.com, jutta.wiemhoff@actelion.com, drugsafetyCH@actelion.com, paul.vangiersbergen@actelion.com, helpdesk@actelion.com, amanda.wan@actelion.com, christian.albrich@actelion.com, jo.lonergan@actelion.com, marla.brickley@actelion.com, matt.smith@actelion.com, mrk@actelion.com, usmedinfo@actelion.com, info@actelion.com, Nadine.Bacher@actelion.com, sandra.bucher@actelion.com, Erica.Copeland@actelion.com, Katie.Holm@actelion.com

SENDING EMAILS IN BULK:
1. Some emails in large blocks will inevitably bounce. WHY? They are obtained from websites that haven't been updated. They are disabled or blocked in response to ongoing activist campaigns.
2. To BLIND-COPY a block of emails, so recipients don't see huge email list:
   • COPY/PASTE a block of emails into the Bcc: line of your email.
   • TYPE YOUR OWN EMAIL in the To: line.
   • Personalize, sign, COPY/PASTE letter portion of alert into body of your email.
   • Click SEND.
   • REPEAT FOR EACH BLOCK OF EMAILS.
   • Email programs differ in terms of how many addresses you can send to at one time.
     Yahoo, Outlook, Hotmail: Separate emails by a comma (,) and do not exceed 50.
Dear Sir/Madam,

I write to express my concern for the welfare of animals used in the development of Actelion’s biotechnology products. I understand your company employed Huntingdon Life Sciences throughout 2005 to conduct its animal experiments.

Huntingdon’s history includes multiple citations for violations of the U.S. Animal Welfare Act, the arrest of workers on animal cruelty charges, 520 breaches of Good Laboratory Practice in England, and a $50,000 payoff to the U.S. Agriculture Department for falsified records and animal welfare infractions. HLS has acquired a criminal record in the UK for failure to file company accounts on time.

Over the course of six HLS investigations from 1989 to 2005, photos, videos and testimonials have repeatedly shown incompetence, fraudulent recordkeeping, and profound animal cruelty. I respectfully ask you to join the long list of suppliers, financiers and customers who made the ethically responsible decision to sever ties with HLS. If Actelion no longer deals with HLS in any capacity, please send me a written statement so I may share the good news with others.

Despite HLS exposure in the media and worldwide protest against the lab’s animal abuse, nothing much has changed. In late 2005, two former employees of the Beagle Unit left their jobs in disgust with Huntingdon’s sloppy “science” that endangers consumers of HLS-approved products. They were so distressed over the animal suffering they witnessed daily, they chose to publicize what they’d seen during 12 months of employment.

When animals are dosed (using capsule, subcutaneous, oral gavage, infusion, dermal or eye drops) drugs are improperly administered. One worker described “group 5” dogs who were overdosed in studies for an anti-cancer drug. “In the morning, there was blood everywhere. I was shocked, but told to write each dog up as having red-stained feces instead. The next day, one of the dogs was dead in his pen... I was talking to another Team Leader about the study and she said they knew the group 5 was too high a dose and they knew there would be problems, but they went ahead anyway.”

Dogs are not sufficiently anesthetized before invasive procedures. Upon conclusion of an HLS study, test dogs scheduled to die must frequently undergo removal of bone marrow from the chest bone. The dogs are supposed to be sedated near death, but still alive during the painful extraction. “Two team leaders hadn’t given the dog enough anesthetic and it whimpered and moved,” recalls one of the Beagle Unit technicians. “They didn’t give more anesthetic but carried on.

"Most of the staff had a very uncaring attitude towards the animals and they seemed to be able to just ‘switch off’ to what was happening.”

Indeed, the past employee recounts daily blood draws that sometimes became contests to see who could cram in the most dogs before a break. Given exactly two minutes to pull blood from each, careless workers transferred blood into the wrong tubes. “One license holder I worked with would go in and out about five times with the same needle, not hitting the vein. Some dogs would struggle. I saw co-workers grab them by the scruff, shout and swear at them, swing them by the scruff and slap them.”

I urge you to take a moment to view footage shot inside UK and USA Huntingdon labs: http://www.shac.net/movies/videos_cruelty.html. Why risk credibility by association with a facility notorious for brutality toward animals, staff ineptitude, and fabrication of data? I strongly encourage Actelion Pharmaceuticals to issue a straightforward statement that conveys its refusal to work with Huntingdon Life Sciences.

Thank you for your valuable time and consideration,